Given the report that T cells are accumulated in the bone marrow rather than recruited to the GBM tissue due to the lack of Sphingosine 1-phosphate receptor 1 (S1P1) expressed on the surface [25], it seems meaningful to call up anti-tumor T cells onto tumor tissue before therapies targeting immune checkpoint molecules. The gene discussed is S1PR1; the disease is glioblastoma.